Cingulate Inc. Common Stock

CINGNASDAQUSD
5.87 USD
0.19 (3.35%)AT CLOSE (11:59 AM EDT)
5.90
0.02 (0.43%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
5.90
0.02 (0.43%)
🟢Market: OPEN

CING is currently priced at $5.90. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, CING trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 25, 2026.

Open?$5.71
High?$5.94
Low?$5.65
Prev. Close?$5.68
Volume?165.7K
Avg. Volume?162.9K
VWAP?$5.86
Rel. Volume?1.02x
Bid / Ask
Bid?$5.04 × 100
Ask?$6.79 × 100
Spread?$1.75
Midpoint?$5.92
Valuation & Ratios
Market Cap?82.6M
Shares Out?14.5M
Float?8.9M
Float %?65.8%
P/E Ratio?N/A
P/B Ratio?3.52
EPS?-$1.98
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Employees
14
Market Cap
82.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-12-08
Address
1901 W. 47TH PLACE
KANSAS CITY, KS 66205
Phone: (913) 942-2300
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Bullish(+3/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
64
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.79Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.58%High
Short Interest?1.2M
Days to Cover?7.8
Free Float8.9M
Avg Daily Volume154.3K
Settlement Date2026-08-14
Financial Health
Current Ratio?3.50Strong
Quick Ratio?3.50Strong
Cash Ratio?3.29Strong
Debt/Equity?0.22Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
49
3.52FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-2.4CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-122.7%WEAK
ROA?
S&P
3
-87.1%WEAK
Cash Flow & Enterprise
FCF?$-20938584
Enterprise Value?$59.3M
Fundamentals ratios updated end of day